{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:36:15Z","timestamp":1794843375552,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The grant of Key Industrial Innovation Chain (Group) in Agriculture, Shaanxi, China","award":["2022ZDLNY01-10"],"award-info":[{"award-number":["2022ZDLNY01-10"]}]},{"name":"The Public Welfare Research Project of Northwest A&F University Education Development Foundation."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Influenza A viruses (IAVs) cause seasonal influenza epidemics and pose significant threats to public health. However, seasonal influenza vaccines often elicit strain-specific immune responses and confer little protection against mismatched strains. There is an urgent need to develop universal influenza vaccines against emerging and potentially re-emerging influenza virus infections. Multiepitope vaccines combining multiple conserved epitopes can induce more robust and broader immune responses and provide a potential solution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here, we demonstrated that an HA chimeric multiepitope nanoparticle vaccine, delivered intranasally conferred broad protection against challenges with various influenza viruses in mice. The nanoparticle vaccine co-expresses the ectodomain of haemagglutinin (H), three repeated highly conserved ectodomains of matrix protein 2 (M), and the M-cell-targeting ligand Co4B (C) in a baculovirus-insect cell system. These elements (C, H and M) were presented on the surface of self-assembling ferritin (f) in tandem to generate a nanoparticle denoted as CHM-f. Intranasal vaccination with CHM-f nanoparticles elicited robust humoral and cellular immune responses, conferring complete protection against a variety of IAVs, including the A\/PR8\/34 H1N1 strain, the swine flu H3N2 strain, the avian flu H5N8 strain, and H9N2. When CHM-f nanoparticles adjuvanted with CpG IAMA-002, the weight loss protective effect, cellular immune responses and mucosal IgA responses were significantly augmented. Compared with controls, mice immunized with CHM-f nanoparticles with or without CpG IAMA-002 showed significant reductions in weight loss, lung viral titres and pathological changes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that CHM-f nanoparticle with or without CpG IAMA-002 is a promising candidate as a universal influenza vaccine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12951-025-03122-6","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:15:13Z","timestamp":1738649713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine"],"prefix":"10.1186","volume":"23","author":[{"given":"Yongqiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiren","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"3122_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285\u2013300.","journal-title":"Lancet"},{"key":"3122_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020;19:239\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"3122_CR3","doi-asserted-by":"publisher","first-page":"aaa8205","DOI":"10.1126\/science.aaa8205","volume":"348","author":"G Stary","year":"2015","unstructured":"Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348:aaa8205.","journal-title":"Science"},{"key":"3122_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/intimm\/dxu063","volume":"26","author":"T Azegami","year":"2014","unstructured":"Azegami T, Yuki Y, Kiyono H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol. 2014;26:517\u201328.","journal-title":"Int Immunol"},{"key":"3122_CR5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/vaccines10111796","volume":"10","author":"L Li","year":"2022","unstructured":"Li L, Shi N, Xu N, Wang H, Zhao H, Xu H, et al. Safety and viral shedding of live attenuated influenza vaccine (LAIV) in Chinese healthy juveniles and adults: a phase I randomized, double-blind, placebo-controlled study. Vaccines (Basel). 2022;10:1796.","journal-title":"Vaccines (Basel)"},{"key":"3122_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1021\/acs.bioconjchem.7b00738","volume":"29","author":"S Longet","year":"2018","unstructured":"Longet S, Lundahl MLE, Lavelle EC. Targeted strategies for mucosal vaccination. Bioconjug Chem. 2018;29:613\u201323.","journal-title":"Bioconjug Chem"},{"key":"3122_CR7","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.2147\/IJN.S359118","volume":"17","author":"K Zhao","year":"2022","unstructured":"Zhao K, Xie Y, Lin X, Xu W. The mucoadhesive nanoparticle-based delivery system in the development of mucosal vaccines. Int J Nanomed. 2022;17:4579\u201398.","journal-title":"Int J Nanomed"},{"key":"3122_CR8","doi-asserted-by":"publisher","first-page":"e2024998118","DOI":"10.1073\/pnas.2024998118","volume":"118","author":"C Dong","year":"2021","unstructured":"Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, et al. Intranasal vaccination with influenza HA\/GO-PEI nanoparticles provides immune protection against homo-and heterologous strains. Proc Natl Acad Sci. 2021;118:e2024998118.","journal-title":"Proc Natl Acad Sci"},{"key":"3122_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246\u201351.","journal-title":"Science"},{"key":"3122_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","volume":"11","author":"JE Ledgerwood","year":"2011","unstructured":"Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011;11:916\u201324.","journal-title":"Lancet Infect Dis"},{"key":"3122_CR11","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.1021\/acsnano.3c01829","volume":"17","author":"J Pan","year":"2023","unstructured":"Pan J, Wang Q, Qi M, Chen J, Wu X, Zhang X, et al. An intranasal multivalent epitope-based nanoparticle vaccine confers broad protection against divergent influenza viruses. ACS Nano. 2023;17:13474\u201387.","journal-title":"ACS Nano"},{"key":"3122_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","volume":"16","author":"J Sui","year":"2009","unstructured":"Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses. Nat Struct Mol Biol. 2009;16:265\u201373.","journal-title":"Nat Struct Mol Biol"},{"key":"3122_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1126\/science.1192517","volume":"329","author":"CJ Wei","year":"2010","unstructured":"Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010;329:1060\u20134.","journal-title":"Science"},{"key":"3122_CR14","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.1111497108","volume":"108","author":"JR Whittle","year":"2011","unstructured":"Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA. 2011;108:14216\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3122_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"3122_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","volume":"106","author":"I Mellman","year":"2001","unstructured":"Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255\u20138.","journal-title":"Cell"},{"key":"3122_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jconrel.2019.09.002","volume":"311\u2013312","author":"J He","year":"2019","unstructured":"He J, Fan K, Yan X. Ferritin drug carrier (FDC) for tumor targeting therapy. J Control Release. 2019;311\u2013312:288\u2013300.","journal-title":"J Control Release"},{"key":"3122_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/pharmaceutics12070604","volume":"12","author":"S Hong","year":"2020","unstructured":"Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020;12:604.","journal-title":"Pharmaceutics"},{"key":"3122_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499:102\u20136.","journal-title":"Nature"},{"key":"3122_CR20","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.2217\/nnm-2018-0222","volume":"13","author":"CP Karch","year":"2018","unstructured":"Karch CP, Matyas GR, Burkhard P, Beck Z. Self-assembling protein nanoparticles: implications for HIV-1 vaccine development. Nanomed (Lond). 2018;13:2121\u20135.","journal-title":"Nanomed (Lond)"},{"key":"3122_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","volume":"6","author":"W Sun","year":"2021","unstructured":"Sun W, He L, Zhang H, Tian X, Bai Z, Sun L, et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct Target Ther. 2021;6:340.","journal-title":"Signal Transduct Target Ther"},{"key":"3122_CR22","first-page":"1304","volume":"221","author":"Y Yan","year":"2020","unstructured":"Yan Y, Wang X, Lou P, Hu Z, Qu P, Li D, et al. A nanoparticle-based hepatitis C virus vaccine with enhanced potency. J Infect Dis. 2020;221:1304\u201314.","journal-title":"J Infect Dis"},{"key":"3122_CR23","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1016\/j.vaccine.2008.09.061","volume":"26","author":"JM Kyd","year":"2008","unstructured":"Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine. 2008;26:6221\u20134.","journal-title":"Vaccine"},{"key":"3122_CR24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni1101-1004","volume":"2","author":"MR Neutra","year":"2001","unstructured":"Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol. 2001;2:1004\u20139.","journal-title":"Nat Immunol"},{"key":"3122_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nano.2006.07.009","volume":"2","author":"LA Lee","year":"2006","unstructured":"Lee LA, Wang Q. Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine. 2006;2:137\u201349.","journal-title":"Nanomedicine"},{"key":"3122_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.bbagen.2010.03.005","volume":"1800","author":"I Yamashita","year":"2010","unstructured":"Yamashita I, Iwahori K, Kumagai S. Ferritin in the field of nanodevices. Biochim Biophys Acta. 2010;1800:846\u201357.","journal-title":"Biochim Biophys Acta"},{"key":"3122_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12977-015-0210-4","volume":"12","author":"K Sliepen","year":"2015","unstructured":"Sliepen K, Ozorowski G, Burger JA, van Montfort T, Stunnenberg M, LaBranche C, et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology. 2015;12:82.","journal-title":"Retrovirology"},{"key":"3122_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.24.436523","author":"MG Joyce","year":"2021","unstructured":"Joyce MG, King HAD, Naouar IE, Ahmed A, Peachman KK, Cincotta CM, et al. Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.03.24.436523.","journal-title":"bioRxiv"},{"key":"3122_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.vetmic.2015.03.005","volume":"177","author":"J Park","year":"2015","unstructured":"Park J, Seo KW, Kim SH, Lee HY, Kim B, Lim CW, et al. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model. Vet Microbiol. 2015;177:142\u201353.","journal-title":"Vet Microbiol"},{"key":"3122_CR30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.vaccine.2021.12.057","volume":"40","author":"YL Yang","year":"2022","unstructured":"Yang YL, Kim J, Jeong Y, Jang YS. Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection. Vaccine. 2022;40:714\u201325.","journal-title":"Vaccine"},{"key":"3122_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1089\/ars.2021.0033","volume":"35","author":"M Fl\u00f3rido","year":"2021","unstructured":"Fl\u00f3rido M, Chiu J, Hogg PJ. Influenza a virus hemagglutinin is produced in different disulfide-bonded states. Antioxid Redox Signal. 2021;35:1081\u201392.","journal-title":"Antioxid Redox Signal"},{"key":"3122_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","volume":"9","author":"YH Jang","year":"2019","unstructured":"Jang YH, Seong BL. The quest for a truly universal influenza vaccine. Front Cell Infect Microbiol. 2019;9:344.","journal-title":"Front Cell Infect Microbiol"},{"key":"3122_CR33","doi-asserted-by":"publisher","first-page":"e0124677","DOI":"10.1371\/journal.pone.0124677","volume":"10","author":"VR Simhadri","year":"2015","unstructured":"Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, et al. A human anti-M2 antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine secretion by resting and cytokine-preactivated natural killer (NK) cells. PLoS ONE. 2015;10:e0124677.","journal-title":"PLoS ONE"},{"key":"3122_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fmicb.2020.00135","volume":"11","author":"OA Vogel","year":"2020","unstructured":"Vogel OA, Manicassamy B. Broadly protective strategies against influenza viruses: universal vaccines and therapeutics. Front Microbiol. 2020;11:135.","journal-title":"Front Microbiol"},{"key":"3122_CR35","doi-asserted-by":"publisher","first-page":"1336239","DOI":"10.3389\/fimmu.2024.1336239","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu S, Li B, Sun X, Pan Q, Zheng Y, et al. A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus. Front Immunol. 2024;15:1336239.","journal-title":"Front Immunol"},{"key":"3122_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.smim.2006.12.001","volume":"19","author":"HK Lee","year":"2007","unstructured":"Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol. 2007;19:48\u201355.","journal-title":"Semin Immunol"},{"key":"3122_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/79734","volume":"1","author":"M Moser","year":"2000","unstructured":"Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1:199\u2013205.","journal-title":"Nat Immunol"},{"key":"3122_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer F. The human antibody response to influenza a virus infection and vaccination. Nat Rev Immunol. 2019;19:383\u201397.","journal-title":"Nat Rev Immunol"},{"key":"3122_CR39","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767\u201377.","journal-title":"J Hyg (Lond)"},{"key":"3122_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","volume":"30","author":"S Black","year":"2011","unstructured":"Black S, Nicolay U, Vesikari T, Knuf M, Giudice GD, Cioppa GD, et al. Hemagglutination inhibition antibody titres as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"3122_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.","journal-title":"BMC Med Res Methodol"},{"key":"3122_CR42","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1128\/JVI.02013-05","volume":"80","author":"S Tengvall","year":"2006","unstructured":"Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol. 2006;80:5283\u201391.","journal-title":"J Virol"},{"key":"3122_CR43","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.4049\/jimmunol.166.5.3451","volume":"166","author":"WS Gallichan","year":"2001","unstructured":"Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001;166:3451\u20137.","journal-title":"J Immunol"},{"key":"3122_CR44","doi-asserted-by":"publisher","first-page":"10713","DOI":"10.1038\/s41598-018-28281-5","volume":"8","author":"YL Lin","year":"2018","unstructured":"Lin YL, Chow YH, Huang LM, Hsieh SM, Cheng PY, Hu KC, et al. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Sci Rep. 2018;8:10713.","journal-title":"Sci Rep"},{"key":"3122_CR45","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.vaccine.2004.08.019","volume":"23","author":"AB Nesburn","year":"2005","unstructured":"Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V, BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine. 2005;23:873\u201383.","journal-title":"Vaccine"},{"key":"3122_CR46","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1038\/s41467-023-39560-9","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jiang Y, He J, Chen J, Qi R, Yuan L, et al. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat Commun. 2023;14:4117.","journal-title":"Nat Commun"},{"key":"3122_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2017.07.012","volume":"530","author":"B Bernocchi","year":"2017","unstructured":"Bernocchi B, Carpentier R, Betbeder D. Nasal nanovaccines. Int J Pharm. 2017;530:128\u201338.","journal-title":"Int J Pharm"},{"key":"3122_CR48","doi-asserted-by":"publisher","first-page":"12530","DOI":"10.1002\/jcp.28120","volume":"234","author":"SMG Hayat","year":"2019","unstructured":"Hayat SMG, Darroudi M. Nanovaccine: a novel approach in immunization. J Cell Physiol. 2019;234:12530\u20136.","journal-title":"J Cell Physiol"},{"key":"3122_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","volume":"14","author":"J L\u00f3pez-Sagaseta","year":"2016","unstructured":"L\u00f3pez-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58\u201368.","journal-title":"Comput Struct Biotechnol J"},{"key":"3122_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7150\/ntno.19796","volume":"1","author":"S Chattopadhyay","year":"2017","unstructured":"Chattopadhyay S, Chen JY, Chen HW, Hu CJ. Nanoparticle vaccines adopting virus-like features for enhanced Immune Potentiation. Nanotheranostics. 2017;1:244\u201360.","journal-title":"Nanotheranostics"},{"key":"3122_CR51","doi-asserted-by":"publisher","first-page":"e2006000","DOI":"10.1002\/smll.202006000","volume":"17","author":"L Qin","year":"2021","unstructured":"Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine-based strategies to Overcome challenges in the whole vaccination Cascade for Tumor Immunotherapy. Small. 2021;17:e2006000.","journal-title":"Small"},{"key":"3122_CR52","doi-asserted-by":"publisher","first-page":"949779","DOI":"10.3389\/fimmu.2022.949779","volume":"13","author":"Y Pastor","year":"2022","unstructured":"Pastor Y, Ghazzaui N, Hammoudi A, Centlivre M, Cardinaud S, Levy Y. Refining the DC-targeting vaccination for preventing emerging infectious diseases. Front Immunol. 2022;13:949779.","journal-title":"Front Immunol"},{"key":"3122_CR53","doi-asserted-by":"publisher","first-page":"e136653","DOI":"10.1172\/jci.insight.136653","volume":"5","author":"HG Kelly","year":"2020","unstructured":"Kelly HG, Tan HX, Juno JA, Esterbauer R, Ju Y, Jiang W, et al. Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight. 2020;5:e136653.","journal-title":"JCI Insight"},{"key":"3122_CR54","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020;15:406\u201316.","journal-title":"Nat Nanotechnol"},{"key":"3122_CR55","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s12276-022-00859-0","volume":"54","author":"NK Lee","year":"2022","unstructured":"Lee NK, Cho S, Kim IS. Ferritin - a multifaceted protein scaffold for biotherapeutics. Exp Mol Med. 2022;54:1652\u201357.","journal-title":"Exp Mol Med"},{"key":"3122_CR56","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1051\/jbio\/2012027","volume":"206","author":"JV Gonzalez-Aramundiz","year":"2012","unstructured":"Gonzalez-Aramundiz JV, Cordeiro AS, Csaba N, Fuente MD, Alonso MJ. Nanovaccines: nanocarriers for antigen delivery. Biol Aujourdhui. 2012;206:249\u201361.","journal-title":"Biol Aujourdhui"},{"key":"3122_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jconrel.2017.03.033","volume":"263","author":"M Luo","year":"2017","unstructured":"Luo M, Samandi LZ, Wang Z, Chen ZJ, Gao J. Synthetic nanovaccines for immunotherapy. J Control Release. 2017;263:200\u201310.","journal-title":"J Control Release"},{"key":"3122_CR58","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.1503885112","volume":"112","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P, et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc Natl Acad Sci USA. 2015;112:7809\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3122_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2018.00276","volume":"9","author":"E Panagioti","year":"2018","unstructured":"Panagioti E, Klenerman P, Lee LN, van der Burg SH, Arens R. Features of effective T cell-inducing vaccines against chronic viral infections. Front Immunol. 2018;9:276.","journal-title":"Front Immunol"},{"key":"3122_CR60","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","volume":"33","author":"AF Altenburg","year":"2015","unstructured":"Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine. 2015;33:500\u20136.","journal-title":"Vaccine"},{"key":"3122_CR61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/vaccines6020018","volume":"6","author":"EB Clemens","year":"2018","unstructured":"Clemens EB, van de Sandt C, Wong SS, Wakim LM, Valkenburg SA. Harnessing the power of T cells: the promising hope for a universal influenza vaccine. Vaccines (Basel). 2018;6:18.","journal-title":"Vaccines (Basel)"},{"key":"3122_CR62","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nri3152","volume":"12","author":"SL Swain","year":"2012","unstructured":"Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4\u207a T cells in immunity to viruses. Nat Rev Immunol. 2012;12:136\u201348.","journal-title":"Nat Rev Immunol"},{"key":"3122_CR63","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/v11070620","volume":"11","author":"THP Peacock","year":"2019","unstructured":"Peacock THP, James J, Sealy JE, Iqbal M. A global perspective on H9N2 avian influenza virus. Viruses. 2019;11:620.","journal-title":"Viruses"},{"key":"3122_CR64","doi-asserted-by":"publisher","first-page":"1200681","DOI":"10.3389\/fmicb.2023.1200681","volume":"14","author":"S Rafique","year":"2023","unstructured":"Rafique S, Rashid F, Mushtaq S, Ali A, Li M, Luo S, et al. Global review of the H5N8 avian influenza virus subtype. Front Microbiol. 2023;14:1200681.","journal-title":"Front Microbiol"},{"key":"3122_CR65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/zph.12685","volume":"67","author":"W Song","year":"2020","unstructured":"Song W, Qin K. Human-infecting influenza A (H9N2) virus: a forgotten potential pandemic strain? Zoonoses Public Health. 2020;67:203\u201312.","journal-title":"Zoonoses Public Health"},{"key":"3122_CR66","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","volume":"8","author":"MJ Frank","year":"2018","unstructured":"Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov. 2018;8:1258\u201369.","journal-title":"Cancer Discov"},{"key":"3122_CR67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/IJN.S114477","volume":"12","author":"N Hanagata","year":"2017","unstructured":"Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomed. 2017;12:515\u201331.","journal-title":"Int J Nanomed"},{"key":"3122_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1086\/653112","volume":"51","author":"OS S\u00f8gaard","year":"2010","unstructured":"S\u00f8gaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis. 2010;51:42\u201350.","journal-title":"Clin Infect Dis"},{"key":"3122_CR69","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/v14112443","volume":"14","author":"P Tang","year":"2022","unstructured":"Tang P, Cui EH, Chang WC, Yu C, Wang H, Du EQ, et al. Nanoparticle-based bivalent swine influenza virus vaccine induces enhanced immunity and effective protection against drifted H1N1 and H3N2 viruses in mice. Viruses. 2022;14:2443.","journal-title":"Viruses"},{"key":"3122_CR70","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/erv.10.162","volume":"10","author":"C Cooper","year":"2011","unstructured":"Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV\u2122 safety and efficacy. Expert Rev Vaccines. 2011;10:417\u201327.","journal-title":"Expert Rev Vaccines"},{"key":"3122_CR71","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682\u201394.","journal-title":"Lancet"},{"key":"3122_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/eji.200324032","volume":"34","author":"J Vollmer","year":"2004","unstructured":"Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34:251\u201362.","journal-title":"Eur J Immunol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03122-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:15:20Z","timestamp":1738649720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03122-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3122"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03122-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Northwest A&F University Institutional Animal Care and Use Committee (IACUC). The study was conducted in accordance with local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agreed to submit this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}